BEDFORD, Mass., April  15, 2026  (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter

ANIK

Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

Anika Therapeutics to Release Q1 2026 Financial Results Soon

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BEDFORD, Mass., April  15, 2026  (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Anika Therapeutics is scheduled to release its first quarter 2026 financial results on April 29, 2026, followed by a conference call to discuss business highlights. Investors should be prepared for potential direction in share price based on performance metrics revealed during the update.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Anika Therapeutics will report Q1 2026 results on April 29, 2026.</li><li>Conference call set for 8:30 a.m. ET to discuss results.</li><li>The report may indicate ongoing performance in the orthopedic sector.</li><li>Investors should prepare for potential market reactions to earnings updates.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Anika Therapeutics, Inc. (ANIK)</strong>: ANIK&#039;s financial results will be critical for future valuation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as Anika prepares investors for critical financial disclosures. The upcoming earnings report will be pivotal for assessing the company&#039;s operational health and market competitiveness in orthopedics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Financial results could significantly influence investor sentiment and stock volatility.</li><li>Market expectations may swing positively or negatively based on earnings surprise.</li><li>Details on product performance in orthopedic care could impact future pricing.</li><li>Analyst ratings following the report may adjust based on disclosed outcomes.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Anika&#039;s Q1 2026 results will be available before market opens on April 29, 2026.</li><li>The conference call will start at 8:30 a.m. ET.</li><li>Anika focuses on orthopedic pain management and regenerative solutions.</li><li>Company is headquartered in Bedford, Massachusetts.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>ANIK may experience volatility leading up to and following Q1 2026 results.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>BEDFORD, Mass., April  15, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=STMAgvvRjgtvTtJmT0W03vuGgVJGeFOS0wBSjIfHmisVozUNWBdZ4TJbrlEgvl033JC6bW1g-aht6DqFYNl_dkZMs-0FWqWna4xgOjvLJZg=" rel="nofollow" target="_blank">Anika Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ANIK">ANIK</a>), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.</p>  <p>The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 82141. A live audio webcast and accompanying presentation materials will be available in the <a href="https://www.globenewswire.com/Tracker?data=1o92H-v0DlEiKKBSWd-AvXOUxiJv536ifPsaxLw-Cqx7stfrTcYbFG5df7mAyOGQqYczFjOgVfjhNJh9LtHw6jRQxXUnckQsqcX0-AB_ToUEqae6pBcvywZ35ORhQLFs" rel="nofollow" target="_blank">Investor Relations</a> section of Anika&#39;s website, <a href="https://www.globenewswire.com/Tracker?data=dcOBmbalBOkkj-VqHUs-iLs3g9YKua-Jc_0KWvTvDct-OmID-htONeyHA53KNU43AY9hW4sahG2xslLDdxmiTA==" rel="nofollow" target="_blank">www.anika.com</a>. The call will be archived and accessible on the same website shortly after its conclusion.</p>  <p><strong>About Anika</strong></p>  <p><a href="https://www.globenewswire.com/Tracker?data=STMAgvvRjgtvTtJmT0W03vuGgVJGeFOS0wBSjIfHmitsNCWKs0_oFJzOvU5Ha8Wc7E_dS7PP6NFn_DR1RaXQuGHecx052CYq5chAuZ9GgN0=" rel="nofollow" target="_blank"><u>Anika Therapeutics, Inc.</u></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ANIK">ANIK</a>), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit <a href="https://www.globenewswire.com/Tracker?data=dcOBmbalBOkkj-VqHUs-iLAzjlAkuOsIHQAqfPd54eRVEQX2VDRRAZx8f8PpoAObjBnzhEE1WIaswFPNCNxOng==" rel="nofollow" target="_blank"><u>www.anika.com</u></a>.</p>  <p>ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.</p>  <p><strong>For Investor Inquiries:</strong><br></br>Anika Therapeutics, Inc.<br></br>Matt Hall, 781-457-9554<br></br>Executive Director, Corporate Development and Investor Relations<br></br><a href="https://www.globenewswire.com/Tracker?data=ioNAvTIsgXlXISulcAzHNrBARo9zVMiCyiqFWX7eDgMTR-mmV7GuM1fivuMy6hvJMdX-S8j0ajEJReAIYfkDmg6dyJc9pdHye42yI9DQJG24Z6uCNaBQ3Bo80ZMcehLd" rel="nofollow" target="_blank">investorrelations@anika.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5MDM1NyM3NTM1NjI3IzIwMDY1MzA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YTZkMzlhNjUtN2Y4ZC00MzU3LTg5OTktNTRjNzg4MmQ3NjBlLTEwMTgxMDMtMjAyNi0wNC0xNS1lbg==/tiny/Anika-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/342e50d9-f0e4-4e79-b568-840299c2045d"><img src="https://ml.globenewswire.com/media/342e50d9-f0e4-4e79-b568-840299c2045d/small/anika-new-logo-blue-1200x628-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

Anika Therapeutics is scheduled to release its first quarter 2026 financial results on April 29, 2026, followed by a conference call to discuss business highlights. Investors should be prepared for potential direction in share price based on performance metrics revealed during the update.

Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News